KR820001643B1 - Process for the preparation of 6-halo-pregrnanes - Google Patents
Process for the preparation of 6-halo-pregrnanes Download PDFInfo
- Publication number
- KR820001643B1 KR820001643B1 KR7901469A KR790001469A KR820001643B1 KR 820001643 B1 KR820001643 B1 KR 820001643B1 KR 7901469 A KR7901469 A KR 7901469A KR 790001469 A KR790001469 A KR 790001469A KR 820001643 B1 KR820001643 B1 KR 820001643B1
- Authority
- KR
- South Korea
- Prior art keywords
- hydroxy
- halo
- keto
- derivative
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 0 CC1(C(C2)C(CCC(C3(C)C=C4)=C*4O)[C@]33OC3C1)C(*)(*)C2N Chemical compound CC1(C(C2)C(CCC(C3(C)C=C4)=C*4O)[C@]33OC3C1)C(*)(*)C2N 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
내용 없음.No content.
Description
본 발명은 다음 구조식(Ⅲ)의 6α-할로-3-메토-Δ1,4-프레그나디엔 유도체의 제조 방법에 관한 것이다.The present invention relates to a process for the preparation of 6α-halo-3-metho-Δ 1 , 4 -pregnadiene derivative of the following formula (III).
상기 구조식에서 R 및 Z는 수소, 하이드록시, 또는 최대로 탄소수 9의 카복실 산으로부터 유도된 아실옥시이거나, 또는 Z가 하이드록시이고 w가 하이드록시 일 때 α-방위체는의 그룹을 나타내며, w는 수소 또는 하이드록시 또는 메틸이고, X는 할로겐, 특히 불소 및 염소이다.Wherein R and Z are hydrogen, hydroxy, or acyloxy derived from a carboxylic acid of up to 9 carbon atoms, or when Z is hydroxy and w is hydroxy And w is hydrogen or hydroxy or methyl and X is halogen, in particular fluorine and chlorine.
본 발명은 3-케토-9β, 11β-옥시도-Δ1,4-프레그나디엔 유도체를 적합한 아실화제 또는 에테르 화제와 반응시켜 상응하는 3-에놀 유도체를 얻고 이를 적합한 할로겐 화제와 반응시켜 할로겐화시켜 6α-할로-3-케토-Δ1,4-프레그나디엔 유도체 특히 Δ1,4-3-케토-프레그나디엔류의 6α-플루오로 유도체와 같은 강력한 활성을 갖는 스테로이드 화합물을 합성하는 방법에 관한 것이다.The present invention reacts a 3-keto-9β, 11β-oxido-Δ 1 , 4 -pregnadiene derivative with a suitable acylating or ethering agent to give the corresponding 3-enol derivative and reacts with a suitable halogenating agent to halogenate it. by 6α- halo-3-keto -Δ 1, 4 - the synthesis of a steroid compound having a strong activity such as program derivative 6α- fluoro regeuna diene-frame that Nadi yen derivative particularly Δ 1, 4 -3-keto It is about a method.
이들 유도체는 Δ4-3-케토스테로이드로부터 유도된 Δ3,5-디엔-3-올 에스테르 또는 에테르의 할로겐화된 친전자 시약으로 처리하여 통상적으로 제조한다는 사실은 이미 알려져 있다. 위리는 Δ1,4-3-케토화합물로부터 출발하여 동일 반응 경로를 거쳐 성공적으로 반응을 수행할 수 있다는 것을 발견하였다.These derivatives are Δ 4 -3-keto steroid of Δ 3, 5 derived from-the fact that conventional manufacturing processes with the diene 3-ol esters or ethers of halogenated parent E reagent is already known. Wiri has been found that it is possible to carry out the reaction successfully through the same reaction route starting from Δ 1, 4 -3- keto compound.
11-케토 그룹을 지니는 제한된 그룹의 Δ1,4-3-케토 그룹을 에놀화시킬 수 있다는 것이 문헌(미합중국 특허 3506650 및 미합중국 특허 3629299호)에 알려져 있으며, 11-케토그룹을 좀더 활성이 큰 11β-하이드록시 화합물(p-할로 치환체를 지닐수도 있고 지니지 않을수도 있다)로 전환시키는 방법은 매우 복잡하다.11 that the keto group to be having on the nolhwa Δ 1, 4 -3- keto group of a limited group known to the literature (U.S. Patent 3.50665 million and U.S. Patent No. 3,629,299), the large 11-keto group is more active 11β The process of converting to a hydroxy compound (which may or may not have a p-halo substituent) is very complicated.
우리는 놀라웁게도 9β,11β-옥시도-스테로이드를 아실무수물, 이소프로페닐 아세테이트, 트리알킬오르토포메이트 등의 적합한 아실화제나 에테르 화제와 잘 조절한 조건하에서 반응시킨 후 생성된 3-에놀-유도체를 N-할로아마 이드류퍼클, 로릴플루오라이드 등의 적합한 할로겐화제로 할로겐화시켜 9β,11β-옥시도-Δ1, 4-프로그나디엔-3-온류의 3-에놀유도체, 즉, 9β, 11β-옥시도-Δ1,3,5-프레그나트리엔-3-올 3-에스테르류 또는 3-에테르류를 고수율로 제조할 수 있다는 사실을 발견하였다.We surprisingly react the 9β, 11β-oxido-steroids with suitable acylating or etherifying agents such as acyl anhydride, isopropenyl acetate, trialkylorthoformates, etc., under well controlled conditions of 3-enol- The derivatives are halogenated with a suitable halogenating agent such as N-haloamide perchlor, lauryl fluoride and the like to form 3-enol derivatives of 9β, 11β-oxido-Δ 1, 4 -prognadien-3-ones, that is, 9β, 11β- It has been found that oxido-Δ 1,3,5 -pregnatrien-3-ol 3-esters or 3-ethers can be produced in high yield.
할로겐화 반응은 3-에놀-유도체를 미리 분리시키거나 또는 에놀화 반응 혼합물내에서 직접 수행한다. 이 경우에 에놀화 반응이 완결된 후 진공하에서 대부분의 용매 또는 반응물질을 제거하고 다음 단계에서 잔유물을 용매중에 용해시킨다.The halogenation reaction is carried out in advance of the 3-enol-derivatives or directly in the enolation reaction mixture. In this case, after completion of the enolation reaction, most of the solvent or reactants are removed under vacuum and the residue is dissolved in the solvent in the next step.
본 발명의 목적은 9β,11β-3-옥시도-Δ1,4-케토-스테로이드류등의 신규의 스테로이드 중간 물질을 제공하는데 있다.An object of the present invention is to provide novel steroid intermediates such as 9β, 11β-3-oxido-Δ 1 , 4 -keto-steroids.
본 발명의 또다른 목적은 Δ1,4-3-케토스테로이드류의 6-할로, 유도체를 형성시키는 단순화된 공정을 제공하는데 있다.A further object of the present invention to provide a simplified process for forming a 6-halo, derivatives of Δ 1, 4 -3- keto steroids.
본 발명의 장점은 생성된 6-할로 유도체가 일반적으로 α-방위의 에피머이고 적어도 α-에피머가 우위인 혼합물 이라는 사실이다.An advantage of the present invention is the fact that the resulting 6-halo derivatives are generally mixtures in which the a-orientation epimer is at least an α-epimer superior.
통상적인 방법으로 6α-할로-Δ1,4-3-케토-유도체의 에폭시 환을 할로게니드르산으로 개환시키면 상응하는 고활성의 6α,9α-디할로-11β-하이드록시-Δ1,4-프레그나디엔-3-온류가 쉽게 얻어진다.만약 목적하는 최종 생성물이 9-위치에 치환체가 없는 6α-플루오로-유도체일 경우에는 불화수소산과는 다른 할로게니드르산으로 에폭사이드를 개환시키고 이어서 얻어진 9-할로 유도체를 공지의 방법으로 탈할로겐화 시킨다.Conventional manner with a halo-6α- -Δ 1, 4 -3- keto-high activity corresponding to when the ring-opening of the epoxy ring of the derivative with a halo genistein deureu acid 6α, 9α- hydroxy -Δ 1, 4 -11β- a dihalo -Pregnadiene-3-ones are easily obtained. If the desired end product is a 6α-fluoro-derivative without substituents at the 9-position, the epoxides are ring-opened with halogenideric acid other than hydrofluoric acid. The resulting 9-halo derivative is then dehalogenated by a known method.
본 발명에 따른 방법은 다음의 도식으로 표현할 수 있다.The method according to the invention can be represented by the following scheme.
상기 구조식에서 R은 수소 또는 하이드록시 또는 아실옥시이고,R in the above formula is hydrogen or hydroxy or acyloxy,
R'는 아실 또는 알킬이고,R 'is acyl or alkyl,
Z는 수소 또는 하이드록시 또는 아실옥시이고,Z is hydrogen or hydroxy or acyloxy,
w는 수소, 하이드록시 또는 메틸이고,w is hydrogen, hydroxy or methyl,
X는 할로겐이고,X is halogen,
Y는 수소 또는 할로겐이다.Y is hydrogen or halogen.
출발물질(Ⅰ)에서 Z가 하이드록시이고 w가 α-방위의 하이드록시일때는 이들 시스-디올류는 한분자의 케톤 또는 알데하이드로 축합시켜 16α,17α-아세탄, 또는 케탄 그룹을 형성시키며 ; α-방위의 R 또는 Z 또는 w가 구조식(Ⅰ)화합물에서 하이드록시로 존재할 때는 Δ1,4-3-케톤의 에놀화 반응은 에놀에스테르화 반응내에 속하며 이때 상기 그룹은 아실화하여 구조식(Ⅱ),(Ⅲ) 및 (Ⅳ)의 화합물에서 반응에 사용된 에놀 에스테르 화제와 동일한 아실 잔기를 지니는 아실옥시 그룹으로 존재한다.In the starting material (I), when Z is hydroxy and w is α-direction hydroxy, these cis-diols are condensed with a single molecule of ketone or aldehyde to form 16α, 17α-acetan, or ketan group; When the R or Z or w of orientation present in the α- hydroxy in formula (Ⅰ) a compound Δ 1, nolhwa the reaction of 4-3-ketone belongs in the enol esterification reaction wherein the group is acylated by the following structural formula (Ⅱ In the compounds of (III) and (IV) are present as acyloxy groups with the same acyl moiety as the enol esterification agent used in the reaction.
이와 같은 아실옥시그룹은 유리 하이드록시 유도체를 얻기 위하여 통상의 방법으로 제거시킬 수도 있고 또는 그대로 보존할 수도 있다.Such acyloxy group may be removed by a conventional method or may be preserved as it is in order to obtain a free hydroxy derivative.
다음의 실시예들은 본 발명을 설명해준다.The following examples illustrate the invention.
[실시예 1]Example 1
a) 9β,11β-옥시도-16α,17α,21-트리하이드록시-프레그나-1,4-디엔-3,20-디온 16,17-아세토나이드 21-아세테이트(10g)와 p-톨루엔 설폰산 모노하이드레이트(1.5g)의 이소프로페닐 아세테이트 용액(100ml)을 때때로 이소프로페닐 아세테이트를 가하여 부피를 100ml로 유지하면서 10시간동안 증류시킨다. 이 용액을 실온으로 냉각하고 10g의 고체 탄산수소나트륨을 가한다.a) 9β, 11β-oxido-16α, 17α, 21-trihydroxy-pregna-1,4-diene-3,20-dione 16,17-acetonide 21-acetate (10 g) and p-toluene sulfone A solution of isopropenyl acetate (100 ml) of phonic acid monohydrate (1.5 g) is sometimes distilled for 10 hours while adding isopropenyl acetate to maintain the volume at 100 ml. The solution is cooled to room temperature and 10 g of solid sodium hydrogen carbonate is added.
잔존하는 반응물질을 진공하에서 증류시켜 제거하고 잔유물을 에테르와 물과 함께 진탕한 후 층을 분리하여 수층을 에테르로 두 번 추출한다. 추출물을 모아 물로 세척한 후 이어서 염화나트륨 용액으로 세척하여 무수 황산 나트륨상에서 탈수 건조시킨다. 진공하에서 용매를 제거하고 잔유물을 메탄올로부터 결정화시키면 3,2-디아세톡시-9β, 11β-옥시드-16α, 17α-디하이드록시-프레그나-1,3,5-트리엔-20-온-16,17-아세토나이드(10g)이 얻어진다. 융점 : 182℃The remaining reactant is distilled off under vacuum, the residue is shaken with ether and water, the layers are separated and the aqueous layer is extracted twice with ether. The extracts are combined, washed with water and then with sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was removed under vacuum and the residue was crystallized from methanol to give 3,2-diacetoxy-9β, 11β-oxide-16α, 17α-dihydroxy-pregna-1,3,5-trien-20-one -16,17-acetonide (10 g) is obtained. Melting Point: 182 ℃
[α]D-195°(디옥산)[α] D -195 ° (dioxane)
b) 상기 화합물 (9.5g)의 400ml 테트라하이드로푸란(20%의 물을 함유) 용액중에 퍼클로릴 플루오라이드를 45분간 통한다. 혼합물중에 질소기체를 30분간 통하여 과잉의 반응 물질을 제거하고, 감압하에서 증류시켜 대부분의 용매를 제거한다. 잔유물을 에테르로 추출하고 추출물을 모아 5% 탄산 수소나트륨으로 세척하고 이어서 물로세척 한다. 무수 황산나트륨 상에서 건조시킨후 진공하에서 용매를 제거하고 잔유물을 메탄올로 처리하면 6α-플루오로-9β,11β-옥시도-16α,17α 21-트리하이드록시프레그나-1,4-디엔-3,20-디온 16,17-아세토나이드 21-아세테이트(7.0g)가 얻어진다.b) Perchloryl fluoride is passed through a solution of compound (9.5 g) in 400 ml tetrahydrofuran (containing 20% water) for 45 minutes. Nitrogen gas is removed from the mixture for 30 minutes to remove excess reactants and distilled under reduced pressure to remove most of the solvent. The residue is extracted with ether, the extracts are combined, washed with 5% sodium hydrogen carbonate and then washed with water. After drying over anhydrous sodium sulfate, the solvent was removed under vacuum and the residue was treated with methanol to give 6α-fluoro-9β, 11β-oxido-16α, 17α 21-trihydroxypregna-1,4-diene-3,20 Dion 16,17-acetonide 21-acetate (7.0 g) is obtained.
[α]D+59°(디옥산)[α] D + 59 ° (dioxane)
상기 화합물을 불화수소로 통상의 방법으로 처리하면, 플루오시노나이드가 얻어지는데, 이는 필요한 경우 탈아실시키면 플루오로시놀론 아세토나이드가 얻어진다. 이는 공지에 방법에 따라 제조된 화합물과 물리화학적 성질이 동일하다.Treatment of the compound with hydrogen fluoride in a conventional manner yields fluorinide, which, if necessary, deacylated yields fluorocinolone acetonide. It has the same physical and chemical properties as the compound prepared according to the known method.
[실시예 2]Example 2
9β,11β-옥시도-17α,21-디하이드록시프레그나-1,4-디엔-3,20-디온 5g을 실시예 1a와 같이 이소프로페닐아세테이트와 반응시킨다. 반응 물질을 제거하고 잔유물을 수성 테트라하이드로푸란(200ml)중에 용해시킨 후 실시예 1b에 따라 퍼클로릴 플루오라이드로 처리하면 6α-플루오로-9β11β-옥시도-17α, 21-디하이드록시프레그-1,4-디엔-3,20-디온-17, 21-디아세테이트(3,4g)이 얻어진다. 융점 224℃(분해)5 g of 9β, 11β-oxido-17α, 21-dihydroxypregna-1,4-diene-3,20-dione are reacted with isopropenyl acetate as in Example 1a. The reaction mass was removed and the residue was dissolved in aqueous tetrahydrofuran (200 ml) and treated with perchloryl fluoride according to Example 1b to 6α-fluoro-9β11β-oxido-17α, 21-dihydroxypreg -1,4-diene-3,20-dione-17,21-diacetate (3,4 g) is obtained. Melting Point 224 ° C (Decomposition)
[α]D+3.14°(디옥산)[α] D + 3.14 ° (dioxane)
상기 화합물을 통상의 방법으로 처리하면 6α,9α-디플루오로-프레드니솔론 디아세테이트가 얻어진다. 이를 알칼리 탈아실화시키면 6α,9α-디플루오로프레드니솔론이 얻어지는데 이는 공지의 방법에 따라 제조한 화합물과 물리화학적 성질이 동일하다.Treatment of the compound by conventional methods yields 6α, 9α-difluoro-prednisolone diacetate. Alkaline deacylation gives 6α, 9α-difluoroprednisolone, which has the same physicochemical properties as the compound prepared according to a known method.
[실시예 3]Example 3
9β,11β-옥시도-16α-메틸-17α,21-디하이드록시프레그나-1,4-디엔-3,20-디온 12g을 실시예 2와 같이 처리하고 조(粗) 6α-플루오로-9β, 11β-옥시도-16α-메틸-17α, 21-디하이드록시프레그나1,4-디엔-3,20-디온 17,21-디아세테이트(8.7g)을 메틸렌클로라이드-메탄올의 혼합물중에 현탁시키고 질소기체하의 실온에서 촉매량의 금속성 수산화칼륨으로 90분간 처리한다.12 g of 9β, 11β-oxido-16α-methyl-17α, 21-dihydroxypregna-1,4-diene-3,20-dione was treated as in Example 2 and crude 6α-fluoro- 9β, 11β-Oxydo-16α-methyl-17α, 21-dihydroxypregna 1,4-diene-3,20-dione 17,21-diacetate (8.7 g) is suspended in a mixture of methylene chloride-methanol It is then treated with a catalytic amount of metallic potassium hydroxide for 90 minutes at room temperature under nitrogen gas.
수성 아세트산으로 중화시킨후, 감압하에서 용액을 농축시키고 잔유물을메탄올로부터 결정화시키면 6α플루오로-9β,11β-옥시도-16α-메틸-17α,21-디하이드록시프레그나-1,4-디엔-3,20-디온(6.5g)이 얻어진다. 융점 : 268℃(분해)After neutralization with aqueous acetic acid, the solution was concentrated under reduced pressure and the residue was crystallized from methanol to give 6αfluoro-9β, 11β-oxido-16α-methyl-17α, 21-dihydroxypregna-1,4-diene- 3,20-dione (6.5 g) is obtained. Melting Point: 268 ℃ (Decomposition)
[α]D+31°(DMF)[α] D + 31 ° (DMF)
상기 화합물을 통상의 방법으로 불화수소로 처리하면 플루메타손이 얻어지는데, 이는 공지의 방법에 따라 제조한 화합물과 물리-화학적 성질이 동일하다.Treatment of the compound with hydrogen fluoride in a conventional manner yields flumethasone, which has the same physical-chemical properties as the compound prepared according to known methods.
[실시예 4]Example 4
실시예 1b에서 제조한 6α-플루오로 유도체 2g을 10ml의 수성브롬화수소산(48%) (사전에 15℃로 냉각시킨것)에 심하게 교반하면서 적가, 0℃에서 2시간동안 방치하고 이어서 과잉의 탄산나트륨 얼음액에 붓는다. 메틸렌 클로라이드로 추출하고 메틸렌 클로라이드-메탄올로부터 결정화시키면 6α-플루오로-9α-브로모-11β,16α,17α,21-테트라 하이드록시프레그나-1,4-디엔-3, 20-디온 16,17-아세토나이드 21-아세테이트(2.15g)이 얻어진다. 융점 : 218℃(분해)2 g of the 6α-fluoro derivative prepared in Example 1b was added dropwise to 10 ml of aqueous hydrobromic acid (48%) (precooled to 15 DEG C) with stirring, and left at 0 DEG C for 2 hours, followed by excess sodium carbonate. Pour into ice solution. Extracted with methylene chloride and crystallized from methylene chloride-methanol gave 6α-fluoro-9α-bromo-11β, 16α, 17α, 21-tetra hydroxypregna-1,4-diene-3, 20-dione 16,17 Acetonide 21-acetate (2.15 g) is obtained. Melting Point: 218 ° C (Decomposition)
[α]D+106.4°(디옥산)[α] D + 106.4 ° (dioxane)
상기 화합물을 공지의 공정에 따라 9-탈브롬화시키면 플루니솔리드의 21-아세테이트가 어어진다.9-debromination of the compound according to known procedures freezes 21-acetate of flunisolid.
[실시예 5]Example 5
a) 9β, β-옥시도-16α,17α,21-트리하이드록시프레그나-1,4-디엔-3,20-디온 16,17-아세트나이드 21-아세테이트(10g)의 테트라하이드로푸란(50ml) 현탁액중에 메틸오르토포메이트(10ml), 무수 메탄올(20ml), p-톨루엔-설폰산(400mg)을 가한다음 이 혼합물을 실온에서 교반한다.a) Tetrahydrofuran (50 ml) of 9β, β-oxido-16α, 17α, 21-trihydroxypregna-1,4-diene-3,20-dione 16,17-acetide 21-acetate (10 g) Methylorthoformate (10 ml), methanol (20 ml) and p-toluene-sulfonic acid (400 mg) are added to the suspension, followed by stirring at room temperature.
출발물질을 용해하고 반응 혼합물을 총 6시간동안 교반한다. 피리딘(1ml)을 가하고 이 용액을 감압하에서 증류시킨후 잔유물을 메탄올로부터 결정화시키면 3-메톡시-9, β, 11β-옥시드-16α, 17α, 21-트리하이드록시프레그니-1,3,5-트리엔-20-온-16,17-아세토나이드 21-아세테이트(5g)가 얻어진다.The starting material is dissolved and the reaction mixture is stirred for a total of 6 hours. Pyridine (1 ml) was added and the solution was distilled off under reduced pressure and the residue was crystallized from methanol to give 3-methoxy-9, β, 11β-oxide-16α, 17α, 21-trihydroxypregni-1,3, 5-triene-20-one-16,17-acetonide 21-acetate (5 g) is obtained.
융점 172℃Melting point 172 ℃
[α]D-164℃(디옥산)[α] D -164 ° C (dioxane)
b) 상기 화합물(3g)의 피리딘(60ml) 용액에 퍼 클로릴플루오라이드를 10분간 통하고 용액에 잘소기체를 통하여 과잉의 반응물질을 제거한후 얼음을 물중에 붓는다. 결정성 고체를 여과하여 물로 잘씻고 건조시킨후 메탄올로부터 결정화시키면 6α-플루오로-9β, 11β-옥시드-16α, 17α, 21-트리하이드록시프레그나-1,4-디엔-3, 20-디온 16,17-아세토나이드 21-아세테이트(2g)가 얻어진다. (실시예 1b의 생성물과 동일함)b) After passing through perchloryl fluoride for 10 minutes to a pyridine (60 ml) solution of the compound (3 g), the excess reactant is removed from the solution through a gaseous gas, and ice is poured into water. The crystalline solid was filtered, washed well with water, dried and crystallized from methanol to give 6α-fluoro-9β, 11β-oxide-16α, 17α, 21-trihydroxypregna-1,4-diene-3, 20- Dion 16,17-acetonide 21-acetate (2 g) is obtained. (Same as the product of Example 1b)
c) a)에서 얻어진 3-메틸-에놀에테르(2g)의 아세톤(40ml) 용액을 무수 초산나트륨(0.4g) 물(6ml), N-클로로숙신이미드(1.0kg)로 처리하고, 이 혼합물을 하룻밤 교반한후 얼음물에 붓는다. 침전을여과하여 모으고 물로 잘 세척한후, 건조시키고 메탄올로 처리하면 6α-플루오로-9β, 11β-옥시드-16α, 17α, 21-트리하이드록시프레그나-1,4-디엔-3, 20-디온 16,17-아세트나이드 21-아세테이트(1.5g)가 얻어진다. 융점 : 199℃c) Acetone (40 ml) solution of 3-methyl-enol ether (2 g) obtained in a) was treated with anhydrous sodium acetate (0.4 g) water (6 ml), N-chlorosuccinimide (1.0 kg), and this mixture After stirring overnight, pour in ice water. The precipitate was collected by filtration, washed well with water, dried and treated with methanol to give 6α-fluoro-9β, 11β-oxide-16α, 17α, 21-trihydroxypregna-1,4-diene-3, 20 Dion 16,17-acetide 21-acetate (1.5 g) is obtained. Melting Point: 199 ℃
[α]D+53(디옥산).[α] D +53 (dioxane).
[실시예 6]Example 6
실시예 5a에 따라, 9β,11β-옥시도-16α-메틸-21-하이드록시프레그나-1,4-디엔-3,20-디온을 메틸 오르토포메이드와 반응시키고 감압하에서 대부분의 용매를 제거한후 잔유물을 피리딘중에 용해시켜 실시예 5b에서와 같이 퍼클로릴 플루오라이드로 처리하면 6α-플루오로-9β, 11β-옥시드-16α-메틸-21-하이드록시프레그나-1,4-디엔-3, 20-디온-21-아세테이트가 얻어진다. 융점 : 178℃According to Example 5a, 9β, 11β-oxido-16α-methyl-21-hydroxypregna-1,4-diene-3,20-dione was reacted with methyl orthoformate and most of the solvent was removed under reduced pressure. The residue was then dissolved in pyridine and treated with perchloryl fluoride as in Example 5b to give 6α-fluoro-9β, 11β-oxide-16α-methyl-21-hydroxypregna-1,4-diene- 3, 20-dione-21-acetate is obtained. Melting Point: 178 ℃
[α]D+87°(디옥산)[α] D + 87 ° (dioxane)
상기 화합물을 통상의 방법으로 불화수소와 반응시켜 디플루오로코폴론의 21-아세테이트로 전환시킨다.The compound is converted to 21-acetate of difluorocopolone by reaction with hydrogen fluoride in a conventional manner.
[실시예 9]Example 9
9β,11β-옥시도-16β-메틸-17α-하이드록시프레그나-1,4-디엔-3,20-디온(5g)을 출발물질로하여 실시예 2와 같이 진행시키면 얻어진다. 6α-플루오로-9β, 11β-옥시드-16α-메틸-17α-하이드록시-프레그나-1,4-디엔-3, 20-디온(3.5g)이 융점 : 212℃(분해).It is obtained by proceeding in the same manner as in Example 2 using 9β, 11β-oxido-16β-methyl-17α-hydroxypregna-1,4-diene-3,20-dione (5 g) as a starting material. 6α-fluoro-9β, 11β-oxide-16α-methyl-17α-hydroxy-pregna-1,4-diene-3, 20-dione (3.5 g) has a melting point of 212 ° C. (decomposition).
[α]D+41.2°(디옥산)[α] D + 41.2 ° (dioxane)
통상의 방법으로 21-하이드록실화된 관능기를 도입하고 불화수소로 9β,11β-옥시도를 개환한후 상기화합물을 디플로라손으로 전환시킨다. 이는 공지의 방법에 따라 제조된 화합물과 물리 화학적 성질이 동일하다.The conventional method is used to introduce 21-hydroxylated functional groups, ring-opening 9β, 11β-oxidos with hydrogen fluoride and converting the compound to diplason. It has the same physical and chemical properties as the compound prepared according to known methods.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR7901469A KR820001643B1 (en) | 1979-05-09 | 1979-05-09 | Process for the preparation of 6-halo-pregrnanes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR7901469A KR820001643B1 (en) | 1979-05-09 | 1979-05-09 | Process for the preparation of 6-halo-pregrnanes |
Publications (1)
Publication Number | Publication Date |
---|---|
KR820001643B1 true KR820001643B1 (en) | 1982-09-13 |
Family
ID=19211588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR7901469A Expired KR820001643B1 (en) | 1979-05-09 | 1979-05-09 | Process for the preparation of 6-halo-pregrnanes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR820001643B1 (en) |
-
1979
- 1979-05-09 KR KR7901469A patent/KR820001643B1/en not_active Expired
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7718793B2 (en) | Method for the preparation of 6-α fluoro corticosteroids | |
US4036831A (en) | Trimethyl siloxane steroid intermediates | |
US20070117974A1 (en) | One-pot processes for preparing prednisolone derivatives | |
CA1159049A (en) | Process for the preparation of 6-halo-pregnanes | |
HU216638B (en) | New method for producing 11-oxo-steroide derivatives | |
EP0061416B1 (en) | Process for the preparation of delta 9(11)- and delta 16-21-chloro-20-keto steroids of the pregnane and d-homopregnane series and their use as intermediates for the synthesis of highly effective corticoids | |
US4255331A (en) | 3-Acetoxy-9β-11β-epoxy-dienes and the preparation of the corresponding 6α-halogen-4-ene-3-ones | |
EP1242444B1 (en) | Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates | |
US20170114088A1 (en) | Process for the preparation of 17-desoxy-corticosteroids | |
KR820001643B1 (en) | Process for the preparation of 6-halo-pregrnanes | |
NO177099B (en) | Analogous Process for Preparing New Therapeutically Active Steroid Derivatives | |
US4021459A (en) | Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy 20-keto-pregnenes | |
CS250695B2 (en) | Method of pregnane derivatives production | |
EP0994119B1 (en) | Stereoselective process for the preparation of the 22R epimer of budesonide | |
JPH085910B2 (en) | 16α-methylation method | |
US4207235A (en) | Selective epoxidation of steroidal bromohydrins | |
HU182775B (en) | Process for preparing new 3-chloro-pregnane derivatives | |
US3980680A (en) | Process for the preparation of 21-desoxy-17-acyloxy-4-pregnenes and of 21-iodo-21-desoxy-17-acyl oxy-4-pregnene intermediates useful therein | |
JPH0518838B2 (en) | ||
US5602248A (en) | Process for preparation of 9α-chloro-11β-formyloxypregna-3,20-diones | |
EP1275656A1 (en) | Preparation of 9alpha-fluoro-11beta-hydroxypregnane 16,17-acetal derivatives | |
HK1027579A (en) | Stereoselective process for the preparation of the 22r epimer of budesonide | |
JPS6363555B2 (en) | ||
EP0502112A1 (en) | Process for dehydrating corticosteroid intermediates | |
NO750119L (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
PG1605 | Publication of application before grant of patent |
St.27 status event code: A-2-2-Q10-Q13-nap-PG1605 |
|
PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 Fee payment year number: 7 Fee payment year number: 6 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10 Fee payment year number: 9 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 19920914 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 19920914 |
|
P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |